Chicago-based alternative real estate investor Harrison Street has entered the UK biotech sector with the acquisition of a portfolio of five life sciences and innovation properties across the country for a price of around £250 mln (€300 mln).
Chicago-based alternative real estate investor Harrison Street has entered the UK biotech sector with the acquisition of a portfolio of five life sciences and innovation properties across the country for a price of around £250 mln (€300 mln).
Three living funds launched this week, including two senior living investment funds focused on the UK and Germany, as investors continue to see value in alternative investment asset classes driven by strong demographic trends.